Entacapone and Prostate Cancer Risk in Patients With Parkinson's Disease. Issue 5 (16th January 2015)

• Record Type: Journal Article
• Authors: Korhonen, Pasi; Kuoppamäki, Mikko; Prami, Tuire; Hoti, Fabian; Christopher, Solomon; Ellmén, Juha; Aho, Valtteri; Vahteristo, Mikko; Pukkala, Eero; Haukka, Jari
• Is Part Of: Movement disorders. Volume 30:Issue 5(2015)
• Page Start: 724
• Page End: 728
• Publication Date: 2015-01-16
• Subjects: Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.26140
• Languages: English
• ISSNs: 0885-3185

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <sec id="mds26140-sec-0001" sec-type="section"> <title>Background</title> <p>The association between Parkinson's disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE‐PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol‐<italic>O</italic>‐methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.</p> </sec> <sec id="mds26140-sec-0002" sec-type="section"> <title>Methods</title> <p>We performed a retrospective cohort study using population‐wide health care registers with patient‐level linkage. Prostate cancer incidence and mortality were modeled by Cox's proportional hazards models.</p> </sec> <sec id="mds26140-sec-0003" sec-type="section"> <title>Results and Conclusions</title> <p>Use of entacapone with <sc>l</sc>‐dopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence (hazard ratio [HR]: 1.05; 95% confidence interval: 0.76‐1.44) or mortality (0.93; 0.43‐1.98). The HR for cumulative entacapone use of >360 days versus never‐use was 0.82 (0.56‐1.18) for prostate cancer incidence and 1.27 (0.60‐2.72) for prostate cancer mortality. © 2015 International Parkinson and Movement Disorder Society © 2015 International Parkinson and Movement Disorder Society</p> </sec> </abstract>